Skip to content

About Us.

Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker-based diagnostic solutions for complex diseases.

Metabolomic Diagnostics

Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker-based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.

This pipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.

Metabolomic Diagnostics has globally recognised expertise in LC-MSMS based translational research and a state of the art LC-MSMS laboratory including sample preparation robotics.

Utilising our  large and comprehensive collection of bio-banked pregnancy-related specimens Metabolomic Diagnostics current focus is on pregnancy health. We have the ability to deliver personalised pregnancy risk assessment solutions by fitting biomarkers to specific patient characteristics.

Screening for Pre-eclampsia risk is the company's current priority.

Our Senior Management Team

Robin Tuytten

Robin Tuytten

Chief Executive Officer

Read More

Hillary Cronin

Hillary Cronin

Chief Innovation Officer

Read More

Paul Hands

Paul Hands

Director

Read More

Louise Kenny

Louise Kenny

Principal Investigator

Read More

Phil Baker

Phil Baker

Principal Investigator

Read More

Diarmuid Cahalane

Diarmuid Cahalane

Director

Read More

Charles Garvey

Charles Garvey

Executive Chairman

Read More

Robin Tuytten

Chief Executive Officer

Dr Tuytten is a globally respected leader in the field of mass spectrometry and women’s health. Prior to his appointment as CEO Robin had been leading the Metabolomic Diagnostics R&D programs. Robin is trained as an analytical chemist and holds a PhD from the University of Antwerp where he developed methodologies for the mass spectrometric analyses of nucleosides and nucleotides. He joined Belgian biomarker company Pronota in 2006. Robin led Pronota’s Preeclampsia biomarker program until he joined Metabolomic Diagnostics. With more than 20 peer-reviewed scientific publications, co-inventorship on several technical and biomarker patent applications including protein biomarkers for PE, a solid track record in commercial biomarker development and a deep knowledge of the field of pregnancy diseases, Robin Tuytten is well positioned to lead the company’s current and future product development efforts.

Hillary Cronin

Chief Innovation Officer

Ms. Cronin has worked in and with several start up/ developing companies and has been closely involved in the day to day operation of expanding businesses in a variety of cross functional roles. Having a solid mix of a technical background (B.Sc) and business experience she recognizes the supports that are required to overcome the challenges associated with commercialising technical products. Hillary has spent her career working at the leading edge of innovation, delivering scientific excellence to the market place.

Paul Hands

Director

A successful business graduate and serial entrepreneur with more than 30 years’ experience in the technology and life science business sectors. He is recognized for an outstanding mix of strategic vision, global management skills and the proven ability to scale a business across several continents. He has successfully completed multiple venture funding rounds and has established an international network of professional associates. Paul has founded a number of technology companies in Ireland, including QCL (acquired by Calyx in 2003) and QUMAS,(acquired by Accelrys in 2013) Paul is a co-founder of Metabolomic Diagnostics.

Louise Kenny

Principal Investigator

Professor Louise Kenny (MB ChB (hons), PhD, MRCOG) is Executive Pro Vice Chancellor, Faculty of Health & Life Sciences, University of Liverpool. Louise’s post-doctoral work mainly investigated the use of metabolomic technology in the development of a screening test for pre-eclampsia. This work attracted the Society for Gynaecological Investigation President’s Award and Plenary Presentation at the annual meeting in Los Angeles, 2005. In 2006, Louise moved to Ireland to take up key role in the development of the new Anu Research Centre at Cork University Maternity Hospital and continued to develop her research programme in uteroplacental insufficiency, adverse pregnancy outcome and pregnancy loss. In 2007, Louise was appointed as a Health Research Board Ireland Clinician Scientist. This 4 year award (of €1.6 million) is underpinning the Screening for Pregnancy Endpoints (SCOPE) Study- a prospective longitudinal case cohort of pregnancy outcome which will also contribute to the world’s largest global pregnancy biobank (see www.scopestudy.net). In July 2009, Louise was awarded a prestigious Principal Investigator Programme grant from Science Foundation Ireland to develop predictive metabolomic markers of poor pregnancy outcome. In addition, she currently holds grants from The Wellcome Trust, The Children’s Medical and Research Foundation, Molecular Medicine Ireland and the Health Research Board of Ireland. In 2013, Louise led a successful bid under the Science Foundation Ireland Research Centres call to establish the first perinatal research centre in Ireland, the Irish Centre for Fetal and Neonatal Translational Research (INFANT)(www.infantcente.ie). Louise’s work has resulted in >200 peer reviewed original papers, reviews and book chapters. She is the co-Editor of the 19th Edition of `Obstetrics by Ten Teachers’- the world’s leading undergraduate textbook in obstetrics and senior Editor of the forthcoming 20th editions of ‘Obstetrics and Gynaecology by Ten Teachers’. In addition, Louise is a reviewer for a wide range of international journals including the American Journal of Obstetrics and Gynecology, the British Journal of Obstetrics and Gynaecology, the British Medical Journal, Clinical Chemistry, the European Journal of Obstetrics and Gynaecology, the Journal of Perinatal Medicine and Reproductive Sciences and research funding bodies such as the Medical Research Council (UK), the Wellcome Trust, Action Research, the British Heart

Phil Baker

Principal Investigator

Professor Baker is Pro-Vice-Chancellor and Head of the College of Life Sciences, Dean of Medicine at University of Leicester. Prior to accepting the position in Leicester Professor Baker lived and worked in New Zealand where he served as Director of the National Research Centre for Growth and Development and held the position of Professor of Maternal & Fetal Health at the University of Auckland. Professor Baker also runs a dedicated pregnancy research centre based in Chongqing Medical University in Western China following his appointment as a National Distinguished Professor by the Chinese Government in 2013. Previously Professor Baker led the medical schools in both Manchester, UK and Alberta, Canada. He also established and then directed the Manchester NIHR Biomedical Research Centre. He has held visiting professorial appointments in Hong Kong, Toronto and Yale. In 2005 he was given the President’s Achievement Award of the Society of Gynecologic Investigation (The first time this award had been made outside North America). He was elected a Fellow of the Academy of Medical Sciences in 2008. He is a world authority in the aetiology and management of pre-eclampsia, having published over 300 scientific articles and 17 textbooks (including the leading UK undergraduate and postgraduate obstetric texts). He has been investigating screening tests for pre-eclampsia for over 20 years. He been awarded grants totaling over £20M for his own research portfolio, including an MRC program grant and a Wellcome Trust Translational award. He has led institutional research applications that have successfully accrued >£50M. Professor Baker was also the principal author of the position paper on “Health of Women and Children”, presented to The Science Academies of the G8 countries, and considered at the G8 Summit held in Huntsville, Ontario, in June 2010.

Diarmuid Cahalane

Director

Diarmuid Cahalane has been consulting to the technology and life sciences sectors for over 20 years. He is recognised for his strengths in risk analysis, remediation, cost reduction and compliance. In 1997, he established his own regulatory consulting company, and went on to work with many of the leading life science companies, including Pfizer, Schering Plough, and Glaxo Smithkline. He maintains contact with the FDA at a high level and recently visited Washington DC to discuss innovation concepts with the FDA, Patient Advocacy Groups and others. He is an expert member of the Irish mirror committee of ISO:TC276 and is also a member of the Preeclampsia Biomarkers Consortium in the United States.

Charles Garvey

Executive Chairman

Charles Garvey is a serial entrepreneur with extensive experience in growing Irish companies internationally. From 1990 to 2003 he was first COO and then CEO of Horizon Technology Group Plc. and took Horizon from a small privately held company to a major European multinational with significant global credentials. Charles took Horizon public on the London and Dublin stock exchange in 2000. Charles continued to work with Horizon right up to its sale to Avnet Corp in 2009. From 2006 to 2011 Charles was CEO of NitroSell Ltd., a SAAS based ecommerce platform, which has generated almost $1B in sales to date. Charles continues to serve as non-executive chairman of NitroSell. For the past six years, Charles has used his proven teambuilding and managerial skills to build a focused, motivated and successful team of life science professionals at Metabolomic Diagnostics. Charles has extensive experience at forging and managing partnerships with major multinational companies and in corporate finance and fundraising through angel investors, VCs, banks and public markets.

Our Advisory Team

Brian Rappold

Prof Jim Roberts

Declan O’Mahoney

Frank Walsh

Bill Liao

Prof Jim Walsh

Investors & Partners

The team at Metabolomic Diagnostics recognise the important contributions our investors and partners make. We welcome opportunities to work in collaboration with universities and private companies to accelerate the development of their technology. Please contact us to discuss investment and collaborations opportunities to help make pregnancies safer.